The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Open accessAbstract
Background: Primary liver cancer, of which around 75–85% is hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China but also may reshape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice and improve the national average 5-year survival rate for patients with liver cancer, as proposed in the “Health China 2030 Blueprint.”
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Liver Transplantation for Hepatocellular Carcinoma: Hangzhou Experiences [RETRACTED]
Zheng, S.-S., Xu, X., Wu, J., Chen, J., Wang, W.-L., Zhang, M., Liang, T.-B., & Wu, L.-M. (2008) · Transplantation · doi:10.1097/tp.0b013e31816b67e4 · Cited by 452
Self-citationRetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Self-citationCancer statistics in China, 2015
Chen, W., Zheng, R., Baade, P. D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X. Q., & He, J. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21338 · Cited by 17,038
Self-citationSorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Self-citationA New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Research works printed but not linked: 68
- 10.3760/cma.j.cn501113-20210408-00174 · doi:10.3760/cma.j.cn501113-20210408-00174
- 10.1016/j.crad.2014.06.016 · doi:10.1016/j.crad.2014.06.016
- 10.1055/s-0043-114672 · doi:10.1055/s-0043-114672
- 10.11152/mu-1276 · doi:10.11152/mu-1276
- 10.1111/jgh.13202 · doi:10.1111/jgh.13202
- 10.11152/mu-1142 · doi:10.11152/mu-1142
- 10.3348/kjr.2015.16.3.449 · doi:10.3348/kjr.2015.16.3.449
- 10.1148/radiol.15141350 · doi:10.1148/radiol.15141350
- 10.1016/s1499-3872(13)60096-x · doi:10.1016/s1499-3872(13)60096-x
- 10.1002/lt.25713 · doi:10.1002/lt.25713
- 10.1245/s10434-013-3001-y · doi:10.1245/s10434-013-3001-y
- 10.1111/1751-2980.12707 · doi:10.1111/1751-2980.12707
- 10.1016/j.ejrad.2011.08.004 · doi:10.1016/j.ejrad.2011.08.004
- 10.1148/rg.317115050 · doi:10.1148/rg.317115050
- 10.1007/s00259-016-3348-y · doi:10.1007/s00259-016-3348-y
- 10.2967/jnumed.115.167338 · doi:10.2967/jnumed.115.167338
- 10.2967/jnumed.116.182022 · doi:10.2967/jnumed.116.182022
- 10.1007/s12072-014-9566-0 · doi:10.1007/s12072-014-9566-0
- 10.1097/MNM.0b013e32835fa552 · doi:10.1097/mnm.0b013e32835fa552
- 10.1155/2018/5638283 · doi:10.1155/2018/5638283
- 10.1016/j.surg.2011.12.002 · doi:10.1016/j.surg.2011.12.002
- 10.1097/MD.0000000000000495 · doi:10.1097/md.0000000000000495
- 10.1007/s00534-010-0314-0 · doi:10.1007/s00534-010-0314-0
- 10.1002/jso.25258 · doi:10.1002/jso.25258
- 10.1016/s1001-9294(15)30016-x · doi:10.1016/s1001-9294(15)30016-x
- 10.3760/cma.j.cn112139-20201110-00791 · doi:10.3760/cma.j.cn112139-20201110-00791
- 10.1016/j.surg.2018.09.016 · doi:10.1016/j.surg.2018.09.016
- 10.1016/j.ijsu.2015.05.009 · doi:10.1016/j.ijsu.2015.05.009
- 10.1002/bjs.6841 · doi:10.1002/bjs.6841
- 10.1067/msy.2000.108659 · doi:10.1067/msy.2000.108659
- 10.2147/OTT.S217123 · doi:10.2147/ott.s217123
- 10.1007/BF02385702 · doi:10.1007/bf02385702
- 10.1097/SLA.0000000000001707 · doi:10.1097/sla.0000000000001707
- 10.1002/jso.23521 · doi:10.1002/jso.23521
- 10.1053/j.gastro.2019.02.046 · doi:10.1053/j.gastro.2019.02.046
- 10.3748/wjg.v11.i8.1215 · doi:10.3748/wjg.v11.i8.1215
- 10.1097/01.sla.0000245829.00977.45 · doi:10.1097/01.sla.0000245829.00977.45
- 10.1159/000082098 · doi:10.1159/000082098
- 10.1200/jco.2020.38.4_suppl.514 · doi:10.1200/jco.2020.38.4_suppl.514
- 10.21037/tgh.2017.08.02 · doi:10.21037/tgh.2017.08.02
- 10.14701/ahbps.2017.21.4.205 · doi:10.14701/ahbps.2017.21.4.205
- 10.1245/s10434-014-3585-x · doi:10.1245/s10434-014-3585-x
- 10.1002/cncr.25314 · doi:10.1002/cncr.25314
- 10.1080/02656736.2019.1692148 · doi:10.1080/02656736.2019.1692148
- 10.1007/s00270-013-0733-9 · doi:10.1007/s00270-013-0733-9
- 10.1097/CMR.0000000000000653 · doi:10.1097/cmr.0000000000000653
- 10.1055/s-0039-1697641 · doi:10.1055/s-0039-1697641
- 10.1007/s00432-013-1568-0 · doi:10.1007/s00432-013-1568-0
- 10.1177/1533033820937002 · doi:10.1177/1533033820937002
- 10.1002/cncr.31334 · doi:10.1002/cncr.31334
- 10.1002/cncr.32502 · doi:10.1002/cncr.32502
- 10.1016/j.ijrobp.2004.05.025 · doi:10.1016/j.ijrobp.2004.05.025
- 10.3390/cancers10120516 · doi:10.3390/cancers10120516
- 10.1016/j.radonc.2019.05.006 · doi:10.1016/j.radonc.2019.05.006
- 10.1159/000343836 · doi:10.1159/000343836
- 10.1186/s12885-020-07087-7 · doi:10.1186/s12885-020-07087-7
- 10.7150/jca.28674 · doi:10.7150/jca.28674
- 10.1093/jjco/hyv205 · doi:10.1093/jjco/hyv205
- 10.21037/apm.2019.11.17 · doi:10.21037/apm.2019.11.17
- 10.1007/s00066-019-01488-9 · doi:10.1007/s00066-019-01488-9
- 10.1118/1.4953190 · doi:10.1118/1.4953190
- 10.1002/cncr.30915 · doi:10.1002/cncr.30915
- 10.1002/jso.24869 · doi:10.1002/jso.24869
- 10.1016/j.jceh.2018.04.002 · doi:10.1016/j.jceh.2018.04.002
- 10.5694/mja2.50483 · doi:10.5694/mja2.50483
- 10.1186/s40064-016-2762-8 · doi:10.1186/s40064-016-2762-8
- 10.1001/archsurg.141.2.191 · doi:10.1001/archsurg.141.2.191
- 10.1258/ar.2010.100369 · doi:10.1258/ar.2010.100369
Cited by
Precision treatment in advanced hepatocellular carcinoma
Yang, X., Yang, C., Zhang, S., Geng, H., Zhu, A. X., Bernards, R., Qin, W., Fan, J., Wang, C., & Gao, Q. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.01.007 · Cited by 429
Self-citationLiu, X., Cai, Y., Zhang, Y., Zhang, H., Tian, S., Gong, Y., Song, Q., Chen, X., Ma, X., Wen, Y., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107526 · Cited by 39
Self-citationYue, X., Wang, Y., Zheng, R., & Li, L. (2025) · Asia-Pacific Journal of Oncology Nursing · doi:10.1016/j.apjon.2025.100665 · Cited by 6
Metadata
- Authors
- Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., Han, G., Yan, Z., Wang, M., Liu, R., Lu, L., Ren, Z., Zeng, Z., Liang, P., Liang, C., Chen, M., Yan, F., Wang, W., Hou, J., Ji, Y., Yun, J., Bai, X., Cai, D., Chen, W., Chen, Y., Cheng, W., Cheng, S., Dai, C., Guo, W., Guo, Y., Hua, B., Huang, X., Jia, W., Li, Q., Li, T., Li, X., Li, Y., Li, Y., Liang, J., Ling, C., Liu, T., Liu, X., Lu, S., Lv, G., Mao, Y., Meng, Z., Peng, T., Ren, W., Shi, H., Shi, G., Shi, M., Song, T., Tao, K., Wang, J., Wang, K., Wang, L., Wang, W., Wang, X., Wang, Z., Xiang, B., Xing, B., Xu, J., Yang, J., Yang, J., Yang, Y., Yang, Y., Ye, S., Yin, Z., Zeng, Y., Zhang, B., Zhang, B., Zhang, L., Zhang, S., Zhang, T., Zhang, Y., Zhao, M., Zhao, Y., Zheng, H., Zhou, L., Zhu, J., Zhu, K., Liu, R., Shi, Y., Xiao, Y., Zhang, L., Yang, C., Wu, Z., Dai, Z., Chen, M., Cai, J., Wang, W., Cai, X., Li, Q., Shen, F., Qin, S., Teng, G., Dong, J., & Fan, J.
- Venue
- Liver Cancer
- Publisher
- S. Karger AG
- Published
- 2023
- Volume
- 12
- Issue
- 5
- Pages
- 405-444
- ISSN
- 1664-5553 (ISSN-L)
- 2235-1795
- OpenAlex
- W4362640431
- Cited by
- 477
- References
- 188
- FWCI
- 66.39
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). https://app.cochat.ai/papers/10.1159/000530495
- The paper
- Zhou, J., Sun, H., Wang, Z., Cong, W., Zeng, M., Zhou, W., Bie, P., Liu, L., Wen, T., Kuang, M., Han, G., Yan, Z., Wang, M., Liu, R., Lu, L., Ren, Z., Zeng, Z., Liang, P., Liang, C., . . . Fan, J. (2023). Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition). Liver Cancer. https://doi.org/10.1159/000530495
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.